24 November 2026 • Press Release

ORYZON selected as an inaugural member of the SIX European Growth Program and included in the new SIX European Growth Index

- **Oryzon is one of 31 European growth companies selected to participate in the program at launch**
- **The initiative brings together companies listed on SIX Swiss Exchange, BME and Aquis Stock Exchange**
- **Inclusion in the program is expected to enhance Oryzon's international visibility and broaden its reach within the global investor community**

MADRID, SPAIN and CAMBRIDGE, MA, UNITED STATES, November 24, 2026 - Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that it has been selected as one of the 31 inaugural members of the SIX European Growth Program (SEGP) and is included in the newly launched SIX European Growth Index.

Officially launched on November 23, 2026, the SIX European Growth Program is a pan-European initiative designed to enhance the international visibility of growth companies listed on SIX Swiss Exchange, BME and Aquis Stock Exchange, connecting them with a broader investor base and fostering a more integrated and competitive European capital markets ecosystem.

As a central component of the program, the SIX European Growth Index provides investors with a dedicated benchmark to identify and track a diversified group of European growth companies across multiple industries, including healthcare and technology.

Oryzon's inclusion in the inaugural cohort represents an opportunity to further strengthen the Company's international capital markets profile, expand its engagement with institutional investors and increase awareness of its innovative epigenetics platform and long-term growth strategy.

Enric Rello, Oryzon's Chief Financial Officer, commented**:** "We are delighted to be among the inaugural members of the SIX European Growth Program. This initiative provides a valuable platform to strengthen Oryzon's international visibility and expand our engagement with the global investment community as we continue to advance our clinical pipeline and execute our long-term growth strategy."

Through its participation in the program, Oryzon will have access to coordinated investor engagement and visibility initiatives, as well as a range of capital markets services designed to support the development and international positioning of European growth companies.

Further information about the program, the index and its inaugural members is available on the official SIX website:

SIX European Growth Program: https://www.six-group.com/en/site/exchanges/european-growth-program.html

SIX European Growth Index: https://www.six-group.com/en/market-data/indices/global/european-growth-index.html

About Oryzon

Founded in 2000 and headquartered in Barcelona, Spain, Oryzon (ISIN: ES0167733015) is a clinical-stage biopharmaceutical company and a European leader in epigenetics, with a strong focus on personalized medicine for central nervous system (CNS) disorders and oncology. Oryzon's team comprises highly experienced pharmaceutical professionals based in Barcelona, Boston, and New Jersey. The Company has an advanced clinical portfolio built around two LSD1 inhibitors: iadademstat, its oncology/hematology program, which is being evaluated in several ongoing Phase I and II studies and has demonstrated strong preliminary clinical activity in acute myeloid leukemia, including a 95% overall response rate (ORR) in first-line AML; and vafidemstat, its lead CNS program, which is Phase III–ready in borderline personality disorder (BPD) and is in a Phase IIb trial in schizophrenia. In addition, Oryzon is advancing a broader epigenetics pipeline targeting other mechanisms, including HDAC6, for which the Company has nominated ORY-4001 as a clinical candidate for potential development in Charcot–Marie–Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and other neurological disorders. The Company also operates a robust platform for biomarker identification and target validation across malignant and neurological diseases. For more information, visit www.oryzon.com

FORWARD-LOOKING STATEMENTS

This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates" and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees, or any person acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, and/or the restated text of the Securities Market Law, approved by Law 6/2023 of 17 March, and its implementing regulations. Nothing in this document constitutes investment advice. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any jurisdiction. The shares of Oryzon Genomics, S.A. may not be offered or sold in the United States of America except pursuant to an effective registration statement under the Securities Act of 1933 or pursuant to a valid exemption from registration.

Spain

Patricia Cobo/Mario Cordera
Atrevia
+34 91 564 07 25
+34 673 33 97 65
pcobo@atrevia.com
mcordera@atrevia.com

Oryzon

Emili Torrell
Chief BD Officer
+34 93 515 1313

etorrell@oryzon.com

IR & Media, Europe & US

Sandya von der Weid
LifeSci Advisors, LLC
+41 78 680 05 38

svonderweid@lifesciadvisors.com